Siglec and anti-Siglec therapies

Gavuthami Murugesan, Bernd Weigle, Paul R. Crocker (Lead / Corresponding author)

Research output: Contribution to journalReview articlepeer-review

Abstract

Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of receptors that bind sialic acids in specific linkages on glycoproteins and glycolipids. Siglecs play roles in immune signalling and exhibit cell-type specific expression and endocytic properties. Recent studies suggest that Siglecs are likely to function as immune checkpoints that regulate responses in cancers and inflammatory diseases. In this review, we discuss strategies to target the Siglec-sialic acid axis in human diseases, particularly cancer, and the possibility of exploiting them for therapeutic intervention.

Original languageEnglish
Pages (from-to)34-42
Number of pages9
JournalCurrent Opinion in Chemical Biology
Volume62
Early online date16 Feb 2021
DOIs
Publication statusE-pub ahead of print - 16 Feb 2021

Keywords

  • Siglec
  • Sialic acid
  • Cancer
  • Inflammation
  • Immune checkpoint

Fingerprint Dive into the research topics of 'Siglec and anti-Siglec therapies'. Together they form a unique fingerprint.

Cite this